OmniAb specializes in therapeutic antibody discovery, providing pharmaceutical partners with access to a diverse range of antibody repertoires and advanced screening technologies. Central to their offerings are proprietary transgenic animals, including the OmniRat, OmniChicken, and OmniMouse, which are genetically engineered to produce high-quality, fully human antibodies. This innovative approach allows for the rapid identification of optimal therapeutic candidates, enhancing the drug development process. The company also utilizes a unique platform called Biological Intelligence™, which powers the immune systems of these transgenic animals, facilitating the generation of optimized antibody candidates tailored for human therapeutics.

In addition to their transgenic platforms, OmniAb employs cutting-edge technologies such as OmniFlic and OmniClic, designed for the discovery of bispecific antibodies, and OmniTaur, which provides cow-derived antibodies for challenging targets. Their capabilities extend to the development of various next-generation antibody-based therapeutics, including antibody-drug conjugates and CAR-T therapies. The integration of in silico tools and machine learning through OmniDeep further enhances their discovery and optimization processes. With a commitment to collaboration, OmniAb partners with a network of contract research organizations to support the generation and characterization of their antibodies, positioning themselves as a leader in the field of antibody engineering and therapeutics.

United States

OmniAb is a leading-edge antibody discovery company that provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening. The company's discovery platform brings a high level of expertise and innovation to therapeutic antibody discovery.

OmniAb

Company Details